e-Therapeutics (ETX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

11.00p
   
  • Change Today:
    -0.15p
  • 52 Week High: 23.10
  • 52 Week Low: 8.13
  • Currency: UK Pounds
  • Shares Issued: 584.34m
  • Volume: 169,640
  • Market Cap: £64.28m

Growth Ratings

EPS Growth shows the relative growth of a company's earnings over the last year.

The rise in total monies receivable for goods / services sold before expenses.

1yr EPS Growth Not Available
1yr Revenue Growth
44.37% below the market average44.37% below the market average44.37% below the market average44.37% below the market average44.37% below the market average
14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average

Income Ratings

The percentage of the share price that a company pays out as dividends over a year.

The percentage change from the previous year in the dividend paid on each share.

Dividend Yield Not Available
1yr DPS Growth Not Available

Valuation Ratings

The share price as a ratio of revenue per share.

The share price as a ratio of net asset value.

Price Sales Ratio
89.47% above the market average89.47% above the market average89.47% above the market average89.47% above the market average89.47% above the market average
77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average
Price Book Ratio
45.91% below the market average45.91% below the market average45.91% below the market average45.91% below the market average45.91% below the market average
8.33% above the sector average8.33% above the sector average8.33% above the sector average8.33% above the sector average8.33% above the sector average

Performance Ratings

In percentage total change in share price over 30 days.

In percentage total change in share price over 3 months.

Price Chg 30d
86.04% below the market average86.04% below the market average86.04% below the market average86.04% below the market average86.04% below the market average
64.91% below the sector average64.91% below the sector average64.91% below the sector average64.91% below the sector average64.91% below the sector average
Price Chg 3m
89.82% above the market average89.82% above the market average89.82% above the market average89.82% above the market average89.82% above the market average
89.47% above the sector average89.47% above the sector average89.47% above the sector average89.47% above the sector average89.47% above the sector average

Technical Ratings

The Relative Strength Index measures a share price relative to itself and its recent history.

Momentum is an oscillator that measures the rate of price change.

RSI
55.61% below the market average55.61% below the market average55.61% below the market average55.61% below the market average55.61% below the market average
59.26% below the sector average59.26% below the sector average59.26% below the sector average59.26% below the sector average59.26% below the sector average
Momentum 20
56.4% below the market average56.4% below the market average56.4% below the market average56.4% below the market average56.4% below the market average
55.56% below the sector average55.56% below the sector average55.56% below the sector average55.56% below the sector average55.56% below the sector average

Management Ratings

Operating Margin is profit as a percentage of sales.

Return on capital employed measures the return from invested and borrowed capital.

Operating Margin
94.59% below the market average94.59% below the market average94.59% below the market average94.59% below the market average94.59% below the market average
77.14% below the sector average77.14% below the sector average77.14% below the sector average77.14% below the sector average77.14% below the sector average
ROCE Not Available

Profitability Ratings

Earnings per share, the company's profitability expressed on a per share basis.

Analysts' estimates of future EPS for the next 2 years.

EPS
57.26% below the market average57.26% below the market average57.26% below the market average57.26% below the market average57.26% below the market average
7.41% above the sector average7.41% above the sector average7.41% above the sector average7.41% above the sector average7.41% above the sector average
Forecast EPS Not Available

Profit/Loss Ratings

Monies produced from sales of goods and services after trade discounts, VAT, etc.

Operating Profit is the profit after deducting operating costs from gross profits.

Turnover
87.66% below the market average87.66% below the market average87.66% below the market average87.66% below the market average87.66% below the market average
60% below the sector average60% below the sector average60% below the sector average60% below the sector average60% below the sector average
Operating Profit Loss
80.68% below the market average80.68% below the market average80.68% below the market average80.68% below the market average80.68% below the market average
48.15% below the sector average48.15% below the sector average48.15% below the sector average48.15% below the sector average48.15% below the sector average

Balance Sheet Ratings

The difference between current assets and current liabilities.

A current asset representing the company's financial liquidity.

Assets
9.45% above the market average9.45% above the market average9.45% above the market average9.45% above the market average9.45% above the market average
42.31% above the sector average42.31% above the sector average42.31% above the sector average42.31% above the sector average42.31% above the sector average
Cash
41.68% above the market average41.68% above the market average41.68% above the market average41.68% above the market average41.68% above the market average
51.85% above the sector average51.85% above the sector average51.85% above the sector average51.85% above the sector average51.85% above the sector average

Director Deal Ratings

The cumulative amount of stocks sold by company directors over 1 year

The cumulative amount of stocks bought by company directors over 1 year

Sells 1y Not Available
Buys 1y
68.47% below the market average68.47% below the market average68.47% below the market average68.47% below the market average68.47% below the market average
93.33% below the sector average93.33% below the sector average93.33% below the sector average93.33% below the sector average93.33% below the sector average

Broker Ratings

The percentage of stockbrokers that rate the company as a Buy

The percentage of stockbrokers that rate the company as a Hold

Brokers Percent Buy Not Available
Brokers Percent Neutral Not Available

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

e-Therapeutics Market Data

Currency UK Pounds
Share Price 11.00p
Change Today -0.15p
% Change -1.35 %
52 Week High 23.10
52 Week Low 8.13
Volume 169,640
Shares Issued 584.34m
Market Cap £64.28m

e-Therapeutics Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
27.91% below the market average27.91% below the market average27.91% below the market average27.91% below the market average27.91% below the market average
48.15% above the sector average48.15% above the sector average48.15% above the sector average48.15% above the sector average48.15% above the sector average
Price Trend
59.31% below the market average59.31% below the market average59.31% below the market average59.31% below the market average59.31% below the market average
15.79% above the sector average15.79% above the sector average15.79% above the sector average15.79% above the sector average15.79% above the sector average
Income Not Available
Growth
15.52% below the market average15.52% below the market average15.52% below the market average15.52% below the market average15.52% below the market average
18.92% below the sector average18.92% below the sector average18.92% below the sector average18.92% below the sector average18.92% below the sector average

e-Therapeutics Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:35 21 @ 11.00p
16:35 2 @ 11.00p
16:35 19 @ 11.00p
16:29 9 @ 10.80p
16:29 9 @ 11.00p

e-Therapeutics Key Personnel

Chair Trevor Mervyn Jones
CEO Ali Mortazavi

Top of Page